SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DaiS who wrote (17875)1/20/1999 4:27:00 PM
From: VLAD  Read Replies (2) of 23519
 
DaiS,

Your government promised a final verdict concerning Viagra on the NHS registry by yesterday but I still don't see any official report. Can you tell us if your press has released a final statement today concerning Viagra? I believe that either way this will set the precident for Viagra policy in other European countries where MUSE will soon be launched.

If the NHS makes it official that they won't pay the Viagra tab it should give MUSE product sales another big advantage ie it is not only SAFER than Viagra but also CHEAPER since the government will cover most of the cost of MUSE. With this scenario the out of pocket expense for MUSE should be about $2.00 and the Viagra will cost about $10.00. Put this scenario in other major European countries and MUSE should be able to have over 10% of the true organic ED population.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News